Genprex to focus its clinical efforts on Oncoprex in combination therapy with Osimertinib for NSCLC

This article was originally published here

On January 14, 2020, the Company received U.S Food and Drug Administration (FDA) Fast Track Designation for its Oncoprex immunogene therapy in combination with the EGFR tyrosine kinase

The post Genprex to focus its clinical efforts on Oncoprex in combination therapy with Osimertinib for NSCLC appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply